Gary Jacob - OKYO Pharma CEO Director

OKYO Stock  USD 1.04  0.03  2.97%   

Insider

Gary Jacob is CEO Director of OKYO Pharma Ltd
Age 77
Address 14/15 Conduit St, London, United Kingdom, W1S 2XJ
Phone44 20 7495 2379
Webhttps://okyopharma.com

Gary Jacob Latest Insider Activity

Tracking and analyzing the buying and selling activities of Gary Jacob against OKYO Pharma stock is an integral part of due diligence when investing in OKYO Pharma. Gary Jacob insider activity provides valuable insight into whether OKYO Pharma is net buyers or sellers over its current business cycle. Note, OKYO Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell OKYO Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

OKYO Pharma Management Efficiency

The company has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 9th of December 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 9th of December 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.
OKYO Pharma Ltd currently holds 7.42 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. OKYO Pharma has a current ratio of 3.11, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about OKYO Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Adi ZuloffShaniClearmind Medicine Common
55
MBA JDCardio Diagnostics Holdings
60
Susan KahlertSenti Biosciences
N/A
Cameron ShawVirax Biolabs Group
37
Gilad BabchukClearmind Medicine Common
N/A
MD MSCandel Therapeutics
53
Rex CFAAnebulo Pharmaceuticals
64
FMEDSCI MDCandel Therapeutics
62
Carrie CoxCandel Therapeutics
66
Timur DoganCardio Diagnostics Holdings
36
Steven BellonFoghorn Therapeutics
59
LLM JDCandel Therapeutics
63
Jason AmelloCandel Therapeutics
56
Michael LaCasciaFoghorn Therapeutics
59
Kenneth CundyAnebulo Pharmaceuticals
65
Meeshanthini DoganCardio Diagnostics Holdings
35
MPH MDFoghorn Therapeutics
51
Deborah KnobelmanSenti Biosciences
50
Jason DavisVirax Biolabs Group
52
Gerald MdFoghorn Therapeutics
N/A
Allan MDFoghorn Therapeutics
49
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Okyo Pharma is traded on NASDAQ Exchange in the United States. OKYO Pharma Ltd (OKYO) is traded on NASDAQ Exchange in USA. It is located in 14/15 Conduit St, London, United Kingdom, W1S 2XJ and employs 8 people. OKYO Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

OKYO Pharma Leadership Team

Elected by the shareholders, the OKYO Pharma's board of directors comprises two types of representatives: OKYO Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OKYO. The board's role is to monitor OKYO Pharma's management team and ensure that shareholders' interests are well served. OKYO Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OKYO Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Beck, Founder
Keeren Shah, Chief Officer
PharmD Clementi, Chief Officer
Rajkumar Patil, Chief Officer
Gary Jacob, CEO Director

OKYO Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OKYO Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with OKYO Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against OKYO Stock

  0.59CTLT CatalentPairCorr
  0.46AKAN Akanda CorpPairCorr
  0.4CVS CVS Health CorpPairCorr
  0.38MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.36SBM Sirona Biochem CorpPairCorr
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether OKYO Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OKYO Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Okyo Pharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Okyo Pharma Ltd Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.57)
Return On Assets
(2.92)
Return On Equity
(29.69)
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.